Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cabozantinib selectively induces proteasomal degradation of p53 somatic mutant Y220C and impedes tumor growth.

The Journal of biological chemistry - 1 Feb 2025

Lv Fang Lin, Zhang Lu, Ji Cheng, Peng Lei, Zhu Mingxian, Yang Shumin, Dong Shunli, Zhou Mingxuan, Guo Fanfan, Li Zhenyun, Wang Fang, Chen Youguo, Zhou Jinhua, Ren Xingcong, Shen Genhai, Yang Jin-Ming, Li Bin, Zhang Yi

Abstract excerpt

Inactivation of p53 by mutations commonly occurs in human cancer. The mutated p53 proteins may escape proteolytic degradation and exhibit high expression in tumors and acquire gain-of-function activity that promotes tumor progression and chemo-resistance. Therefore, selectively targeting of the gain-of-function p53 mutants may serve as a promising therapeutic strategy for cancer prevention and treatment. In this...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anilides
Share to Mice, Nude

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Proteasome Endopeptidase Complex

Share to Proteolysis

Share to Pyridines

Share to Ubiquitin Thiolesterase

Share to Ubiquitination

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 39793887
DOI: 10.1016/j.jbc.2025.108167
PMCID: PMC11847077

Genes

USP7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cabozantinib selectively induces proteasomal degradation of p53 somatic mutant Y220C and impedes tumor growth.PMID 39793887Read ↗

Discovery of Nanomolar-Affinity Pharmacological Chaperones Stabilizing the Oncogenic p53 Mutant Y220CSemantic proximity Read ↗

Small molecules that targeting p53 Y220C protein: mechanisms, structures, and clinical advances in anti-tumor therapySemantic proximity Read ↗

Anticancer therapeutic strategies for targeting mutant p53-Y220CSemantic proximity Read ↗

Ubiquitin-specific protease 7 inhibitors reveal a differentiated mechanism of p53-driven anti-cancer activitySemantic proximity Read ↗

Selective Dual Inhibitors of the Cancer-Related Deubiquitylating Proteases USP7 and USP47Semantic proximity Read ↗

Targeting the Ubiquitin-Mediated Proteasome Degradation of p53 for Cancer TherapySemantic proximity Read ↗

Construction of Small-Molecule Deubiquitinase-Targeting Chimeras to Reactivate and Stabilize Mutant p53 Y220C in Vitro and in Vivo.Semantic proximity Read ↗

Targeting the ubiquitin–proteasome system to activate wild-type p53 for cancer therapySemantic proximity Read ↗

The deubiquitinase inhibitor WP1130 drives nuclear aggregation and reactivation of mutant p53 for selective cancer cell targeting.Semantic proximity Read ↗

Crizotinib Nanomicelles Synergize with Chemotherapy through Inducing Proteasomal Degradation of Mutp53 Proteins.Semantic proximity Read ↗

FBW7-Dependent Mcl-1 Degradation Mediates the Anticancer Effect of Hsp90 Inhibitors.Semantic proximity Read ↗

In vitro screening of compounds for targeting gastric cancer with Y220C p53 mutation: a molecule combining zinc chelation and a Michael acceptor drives CDKN1 and BBC3 expression to restore a p53-dependent cytotoxicity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.